Clinical Trials Directory

Trials / Unknown

UnknownNCT06298981

Pulse Rate and Breathing Rate Accuracy

Pulse Rate and Breathing Rate Accuracy Study - NuraLogix AMC-SDK

Status
Unknown
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
Nuralogix Corporation · Industry
Sex
All
Age
18 Years – 81 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to conduct a Breathing Rate and Pulse Rate accuracy validation comparing the NuraLogix AMC-SDK to the Reference devices, an FDA cleared End Tidal Carbon Dioxide monitor (GE Datex-Ohmeda) and a standard ECG (GE Datex-Ohmeda) derived heart rate reference. This will be done by manually scoring the collected waveform for data analysis.

Conditions

Interventions

TypeNameDescription
DEVICEnoninvasive and investigational NuraLogix AMC-SDKThe NuraLogix AMC-SDK is a noninvasive device that allows for real-time, remote measuring using facial recordings.

Timeline

Start date
2024-02-12
Primary completion
2024-06-30
Completion
2024-06-30
First posted
2024-03-07
Last updated
2024-03-22

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT06298981. Inclusion in this directory is not an endorsement.